FLT3/NPM1 mutation testing-8152
Test info
FLT3 TKD (D835)
Nucleophosmin
This is a qualitative assay intended to aid in the characterization of Acute Myelogenous Leukemia (AML), which may affect treatment options.
This assay should not be used to monitor minimal residual disease.
Specimen
Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting
Lavender (EDTA), 4mL
ACD whole blood
Bone marrow in EDTA
Whole blood:
Lt blue Sodium citrate (NaCit)
Yellow ACD (A or B)
Bone marrow:
Lavender (EDTA), 4mL
Molecular Medicare billing request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.
- Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
- All information requested is required in order for your request to be completed
Ambient (preferred)
Refrigerated
- Improper label (unlabeled or mislabeled)
- Wrong container (anticoagulant or solution)
- Improper blood/anticoagulant ratio
- Delay in transport
- Improper storage
- Inappropriate timing of collection
- Interfering substances
- Leaking container
Performance
Polymerase Chain Reaction (PCR) & Capillary electrophoresis
Clinical and Interpretive info
Not detected
This assay should not be used to monitor minimal residual disease (sensitivity 5% allele fraction).
Billing
81246
81310
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.
- Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
- All information requested is required in order for your request to be completed